Add BrightSurf on Google Email

Howard Hughes Medical Institute


Study Links Colon Cancer To Diabetes Drug

A study published in Nature Medicine suggests that the diabetes drug troglitazone may increase the risk of colon cancer by activating the PPAR receptor, which promotes tumor formation in the colon. The study found that mice treated with troglitazone developed a significantly greater number of colon polyps than those not treated.

SourceHoward Hughes Medical Institute·JournalNature Medicine·DateSep 1, 1998